Build confidence in supporting patients safely and effectively throughout their treatment journey.

By the end of this webinar, participants should be able to:

  • Understand the practice-changing role of immunotherapy in early triple negative breast cancer.
  • Identify common and specific immune-related adverse events (irAEs) seen in eTNBC patients receiving KEYTRUDA®.
  • Distinguish which AEs can be managed in routine practice and which require treatment discontinuation or specialist input.
  • Educate patients effectively on symptoms to report and signs of potential irAEs.
  • Gain confidence in recognising and managing endocrinopathy-related irAEs in eTNBC patients.

Speaker

Julie Hetherington

Nurse Practitioner, Endocrinology & Metabolism

Return to listing